Is CMPS a good stock to buy? We came across a bullish thesis on COMPASS Pathways plc on BioEquity Watch’s Substack. In this ...
Hosted on MSN
Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts
Shares of Compass Pathways Plc. (CMPS) slumped 47% on Monday afternoon after the results from the late-stage trials of COMP360 in treatment-resistant depression fell short of market expectations.
The field of psychedelic medicine is relatively new, and because of this, certain investors consider it to be loaded with potential. That's why even minor events in companies specializing in this can ...
A White House Executive Order over the weekend has some healthcare company stocks soaring today. One big winner is Compass Pathways (NASDAQ: CMPS). Shares of the biotechnology company rocketed more ...
View COMPASS Pathways Plc Sponsored ADR CMPS stock quote prices, financial information, real-time forecasts, and company news from CNN.
Investors might want to bet on COMPASS Pathways PLC Sponsored ADR (CMPS), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...
Compass Pathways plc (NASDAQ:CMPS) released data from the Phase 3 COMP005 trial, the first of two Phase 3 trials evaluating COMP360 for treatment-resistant depression (TRD). Despite meeting the ...
Compass Pathways stock took a hit in early June. Lykos Therapeutics just got some extremely bearish news from regulators. Regulators being skeptical about Lykos' medicine could be bad for Compass. If ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results